Study of KRN23, a Humanized Anti-FGF23 Monoclonal Antibody, in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

Diseases and Conditions Researched

X-linked Hypophosphatemia

What is the purpose of this trial?

UX023-CL201 is a randomized, multicenter, open-label, dose finding, Phase 2 study. The study will be conducted in prepubescent children aged 5-12 years with XLH to assess the pharmacodynamics and safety of KRN23 administered via subcutaneous injections monthly (every 4 weeks) or biweekly (every 2 weeks) for a total of 64 weeks. The study consists of a 16-week individual dose Titration Period, followed by a 48-week Treatment Period. The study will enroll approximately 30 pediatric patients with XLH and radiographic evidence of bone disease. Subjects will need to discontinue oral phosphate and vitamin D metabolite therapy prior to randomization and throughout the duration of the study.

Participation Guidelines

Age: 5 Years - 12 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Ultragenyx Pharmaceutical
Last Updated:
Study HIC#: 1404013753